基于多基因风险评分在PROACT试验中检出亚临床冠状动脉粥样硬化
PROACT试验在生物样本库中邀请40-75岁、无心血管病且未用降脂药的高冠脉多基因风险评分(PRS)成人,评估基因型优先召回策略的可行性与亚临床斑块情况。结果显示64,092名基因分型者中2,495人(3.9%)符合条件但临床风险低,首批204名影像参与者中半数存在亚临床斑块。
要点
- 高CAD PRS者中临床风险低(中位10年ASCVD风险3%),但半数有亚临床冠脉斑块。
- 斑块患病率男性76.2%、女性38.3%,各年龄组均较高。
- 基因型优先召回策略可行,1,314名受邀者中21.5%选择加入、15.5%完成基线影像。
核心结论
- 基因型优先招募策略在预防试验中可行,能发现标准临床评估未检出的高遗传风险亚临床斑块个体。
研究设计与样本
- 基于医院生物样本库的基因型优先、生物样本库支持的临床试验,PROACT 1(NCT05819814)与PROACT 2(NCT05850091)的中期可行性分析。
- 纳入64,092名基因分型参与者,其中2,495名40-75岁、无心血管病、未用降脂药且高CAD PRS者符合条件;报告前1,314名受邀者的招募可行性,以及前204名完成冠状动脉CT血管造影者的斑块患病率。
主要发现
- 64,092名基因分型者中2,495名(3.9%)符合条件且高CAD PRS,尽管临床风险低(中位10年PCE ASCVD风险3%,Q1-Q3:1%-8%)。
- 1,314名受邀者中283名(21.5%)选择加入,204名(15.5%)完成基线影像;选择加入者专科医疗参与度更高且住址更靠近研究地点。
- 截至2025年1月31日首批204名参与者(平均年龄56.3±8.5岁,69%女性)中,102名(半数)存在亚临床斑块;男性患病率76.2%,女性38.3%。
- 参与者心血管健康良好(平均Life's Essential 8评分73.3±11.5,美国平均约65),但亚临床斑块在各年龄组均高发。
临床怎么用
- 对于临床风险低但高CAD PRS的个体,应考虑进一步评估亚临床冠状动脉粥样硬化以指导预防性药物治疗。
- 基因型优先召回策略可用于预防临床试验的招募,但需关注参与者的医疗参与度和地理可及性差异。
局限性
- 本报告为探索性中期可行性分析,样本量有限,斑块患病率基于首批204名完成影像者。
- 受邀者选择加入可能存在选择偏倚,影响结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary artery disease (CAD) polygenic risk scores (PRS) may identify individuals at elevated genetic risk "flying under the radar" in contemporary practice. The aims of the PROACT (Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis) trials are to prospectively identify these individuals, quantify subclinical coronary plaque, and slow its progression with pharmacologic interventions. OBJECTIVES: The aim of this study is to report interim feasibility and implementation findings from PROACT, a genotype-first, biobank-enabled trial, characterizing eligibility yield, callback engagement, and subclinical coronary atherosclerosis on coronary computed tomographic angiography among individuals with high CAD PRS. METHODS: Within a hospital-based biobank, adults 40 to 75 years of age with high CAD PRS, without cardiovascular disease, and not on lipid-lowering therapy were invited. The authors characterize 2,495 eligible individuals with high CAD PRS, report on the feasibility and early operational outcomes of a genotype-first callback strategy for a clinical trial in the first 1,314 invited, and describe plaque prevalence by age and sex in the first 204 participants using coronary computed tomographic angiography. RESULTS: Among 64,092 genotyped participants, 2,495 (3.9%) were eligible and had high CAD PRS despite low clinical risk (median 10-year pooled cohort equations risk for atherosclerotic cardiovascular disease 3%; Q1-Q3: 1%-8%). Recruitment showed high engagement: among 1,314 invited individuals, 283 (21.5%) opted in, and 204 (15.5%) completed baseline imaging. Compared with participants who did not opt in, those who opted in had higher specialty care engagement and lived closer to the study site. Analysis of the first 204 participants enrolled by January 31, 2025 (mean age 56.3 ± 8.5 years, 69% women), showed that despite the low clinical risk and favorable cardiovascular health (mean Life's Essential 8 score 73.3 ± 11.5 vs the U.S. average of ∼65), one-half the participants (102 of 204) had subclinical plaque. Subclinical plaque prevalence was 76.2% in men and 38.3% in women and was high across age groups. CONCLUSIONS: These exploratory findings highlight the feasibility of implementing genotype-first recruitment for prevention trials and reveal a large proportion of "silent" high-genetic risk individuals with subclinical plaque for whom pharmacotherapy could be beneficial but who remain undetected by standard clinical assessments. (Polygenic Risk Based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health [PROACT 1], NCT05819814; Polygenic Risk Based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine [PROACT 2], NCT05850091).
引用
- Abou-Karam R, Kim MS, Jemma Cho SM, et al. Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials. J Am Coll Cardiol. 2026. PMID: 41706060. doi:10.1016/j.jacc.2025.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。